Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
George Poste sold 20,634 shares of EXEL on 16 May at $45.99 per share, worth a total of $949K. They now own 169,020 EXEL shares, or a 11% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
